Crossmark

Clinicians’ attitude towards a placebo-controlled randomised clinical trial investigating the effect of neuraminidase inhibitors in adults hospitalised with influenza

Crossref DOI link: https://doi.org/10.1186/s12913-018-3122-x

Published Online: 2018-05-02

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Bradbury, Naomi

Nguyen-Van-Tam, Jonathan

Lim, Wei Shen http://orcid.org/0000-0002-7694-3051
License Information

Text and Data Mining valid from 2018-05-02
More Information

Article History

Received: 14 March 2018

Accepted: 15 April 2018

First Online: 2 May 2018

Ethics approval and consent to participate

: National regulations did not require formal consent as all participants were healthcare professionals.

: WSL’s institution has received unrestricted investigator-led research funding from Pfizer for a study in which he is Principal Investigator. JSN-V-T’s research group has received investigator-led funding from F.Hoffmann-La Roche; these funds did not support any aspect of the current work. JSN-V-T is currently on secondment to the Department of Health, England and holds an Honorary Contract with Public Health England. The views expressed in this report of not necessarily those of the Department of Health, England or Public Health England.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Document is current

Any future updates will be listed below